Insider · CIK 0001984652
Karen Sims
officer
Files at ABUS (Arbutus Biopharma Corp). First filing Feb 5, 2025, latest Feb 5, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $64k sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ABUS: Arbutus Biopharma Corp
ABUSOct 9, 2026 · close 4.22
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 23Weak | Arbutus Biopharma Corp | $64k 19,348 shares | -15% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 14, 2025 | ABUS Arbutus Biopharma Corp | AGrant or award Common Shares | +49,300 | $0.00 | $0 | 155,494 | Feb 19, 2025 |
| Feb 14, 2025 | ABUS Arbutus Biopharma Corp | AGrant or award Stock Option (Right to Buy)derivative | +200,300 | $0.00 | $0 | 200,300 | Feb 19, 2025 |
| Feb 4, 2025 | ABUS Arbutus Biopharma Corp | SOpen-market sale Common Shares10b5-1 | -19,348 | $3.28 | $64k | 106,194 | Feb 5, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.